About CancerGene Connect
CancerGene Connect is a Healthcare company based in Dallas (United States) founded in 2015, and was acquired by Invitae in June 2017. SaaS-based genetic screening for cancer risk assessment is provided. It operates in the Healthcare and Technology sectors. CancerGene Connect has raised $300 thousand across 1 funding round from investors including Invitae. The company was acqui-hired. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its competitors include Helix, Benchling and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
CancerGene Connect was founded in 2015 in Dallas, United States, as a cloud-based SaaS provider in the health technology sector. Genetic counseling productivity tools, developed by UT Southwestern, are utilized to identify patients with genetic predispositions to cancers. Patient history is gathered remotely, risk assessment models are executed, family trees are constructed, reports are generated for patients, and a comprehensive database is maintained.
- Headquarters Dallas, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website cagene.com
- Social LinkedIn
- Acquired by Invitae (Jun 2017)
Funding Insights of CancerGene Connect
CancerGene Connect has successfully raised a total of $300K through 1 strategic funding round. The most recent funding activity was a Seed round of $300 thousand completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $300,000
- Total Rounds 1
- Last Round Seed — $300,000
- First Round $300,000
(Oct 2016)
All 1 funding rounds of CancerGene Connect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $300,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in CancerGene Connect
CancerGene Connect has secured backing from 1 investor. Prominent investors backing the company include Invitae.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Home-based genetic tests for detecting diseases are provided to individuals. | 2010 | invitae.com | San Francisco, United States |
Investor details for CancerGene Connect
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CancerGene Connect
3 dated milestones of CancerGene Connect across 2 years, from founding to its latest funding, stage changes and deals.
- Founded CancerGene Connect is founded.
- Funding First funding round of $300K.
- Exit Acquired by Invitae.
Competitors of CancerGene Connect
CancerGene Connect has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of CancerGene Connect
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as CancerGene Connect (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CancerGene Connect
CancerGene Connect was founded in 2015 and raised its 1st funding round 1 year after it was founded.
CancerGene Connect is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
CancerGene Connect is a funded company, having raised a total of $300K across 1 funding round to date. The company's 1st funding round was a Seed of $300K, raised on Oct 2016.
CancerGene Connect was founded in 2015 in Dallas, United States, as a cloud-based SaaS provider in the health technology sector. Genetic counseling productivity tools, developed by UT Southwestern, are utilized to identify patients with genetic predispositions to cancers. Patient history is gathered remotely, risk assessment models are executed, family trees are constructed, reports are generated for patients, and a comprehensive database is maintained.
CancerGene Connect's top competitors include Helix, Benchling and BioAge Labs.
CancerGene Connect has 1 investor. Key investors include Invitae.
Yes. CancerGene Connect was acquired by Invitae in June 2017.